
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

March 2019

Commission File Number: 001-38067

**Verona Pharma plc
(Exact Name of Registrant as Specified in Its Charter)**

**3 More London Riverside
London SE1 2RE UK
+44 203 283 4200
(Address of principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☐ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On March 5, 2019, March 7, 2019, and March 11, 2019, Verona Pharma plc issued press releases reporting the purchase of shares by its Chairman, Dr David Ebsworth (the Person Discharging Managerial Responsibilities ("PDMR") announcements, the ("PDMR Announcements")).

The PDMR Announcements are furnished herewith as Exhibit 1.1, 1.2 and 1.3 to this Report on Form 6-K.

EXHIBIT INDEX

Exhibit No.	Description
<u>1.1</u>	<u>PDMR Announcement March 5, 2019.</u>
<u>1.2</u>	<u>PDMR Announcement March 7, 2019.</u>
<u>1.3</u>	<u>PDMR Announcement March 11, 2019.</u>

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

VERONA PHARMA PLC

Date: March 12, 2019

By: /s/ Claire Poll

Name: Claire Poll

Title: Legal Counsel



PDMR Dealing

March 11, 2019, LONDON - Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (the "Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on March 8, 2019, Dr. David Ebsworth, Chairman of the Company, purchased a further 17,500 ordinary shares of 5 pence each in the Company (the "Ordinary Shares") at a price of 57 pence per Ordinary Share and a total purchase price of £9,975.00. Following the acquisition, Dr. Ebsworth will have an interest in the Company of 235,387 Ordinary Shares, representing 0.22% of the Company's issued share capital.

The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

1	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name	David Ebsworth
2	Reason for the notification	
a)	Position/status	Chairman
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	Verona Pharma plc
b)	LEI	213800EVI6O6J3TIAL06

4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 5 pence each GB00BYW2KH80
b)	Nature of the transaction	David Ebsworth purchased 17,500 Ordinary Shares
c)	Price(s) and volume(s)	Price(s) : 57.00 pence per Ordinary Share Volume(s) : 17,500 Ordinary Shares
d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transaction	8 March 2019
f)	Place of the transaction	London Stock Exchange, AIM

For further information, please contact:

Verona Pharma plc
Jan-Anders Karlsson, Chief Executive Officer
Victoria Stewart, Director of Communications
Stifel Nicolaus Europe Limited (Nominated Adviser
and UK Broker)
Stewart Wallace / Jonathan Senior / Ben Maddison

Tel: +44 (0)20 3283 4200
info@veronapharma.com

Tel: +44 (0) 20 7710 7600



PDMR Dealing

March 5, 2019, LONDON - Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (Verona Pharma), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on March 4, 2019, Dr. David Ebsworth, Chairman of the Company, purchased 43,800 ordinary shares of 5 pence each in the Company (the "Ordinary Shares") at a price of 57.00 pence per Ordinary Share and a total purchase price of £24,966. Following the acquisition, Dr. Ebsworth will have an interest in the Company of 191,587 Ordinary Shares, representing 0.18% of the Company's issued share capital.

The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

1	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name	David Ebsworth
2	Reason for the notification	
a)	Position/status	Chairman
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	Verona Pharma plc
b)	LEI	213800EVI6O6J3TIAL06

4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 5 pence each GB00BYW2KH80
b)	Nature of the transaction	David Ebsworth purchased 43,800 Ordinary Shares
c)	Price(s) and volume(s)	Price(s) : 57.00 pence per Ordinary Share Volume(s) : 43,800 Ordinary Shares
d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transaction	4 March 2019
f)	Place of the transaction	London Stock Exchange, AIM

For further information, please contact:

Verona Pharma plc
Jan-Anders Karlsson, Chief Executive Officer
Victoria Stewart, Director of Communications
Stifel Nicolaus Europe Limited (Nominated Adviser
and UK Broker)
Stewart Wallace / Jonathan Senior / Ben Maddison

Tel: +44 (0)20 3283 4200
info@veronapharma.com

Tel: +44 (0) 20 7710 7600



PDMR Dealing

March 7, 2019, LONDON - Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (â€œVerona Pharmaâ€), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on March 6, 2019, Dr. David Ebsworth, Chairman of the Company, purchased 26,300 ordinary shares of 5 pence each in the Company (the â€œOrdinary Sharesâ€) at a price of 56.30 pence per Ordinary Share and a total purchase price of Â£14,806.90 Following the acquisition, Dr. Ebsworth will have an interest in the Company of 217,887 Ordinary Shares, representing 0.21% of the Companyâ€™s issued share capital.

The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

1	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name	David Ebsworth
2	Reason for the notification	
a)	Position/status	Chairman
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	Verona Pharma plc
b)	LEI	213800EVI6O6J3TIAL06

4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 5 pence each GB00BYW2KH80
b)	Nature of the transaction	David Ebsworth purchased 26,300 Ordinary Shares
c)	Price(s) and volume(s)	Price(s) : 56.30 pence per Ordinary Share Volume(s) : 26,300 Ordinary Shares
d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transaction	6 March 2019
f)	Place of the transaction	London Stock Exchange, AIM

For further information, please contact:

Verona Pharma plc
Jan-Anders Karlsson, Chief Executive Officer
Victoria Stewart, Director of Communications
Stifel Nicolaus Europe Limited (Nominated Adviser
and UK Broker)
Stewart Wallace / Jonathan Senior / Ben Maddison

Tel: +44 (0)20 3283 4200
info@veronapharma.com

Tel: +44 (0) 20 7710 7600